The Efficacy, Safety and Tolerability of Canakinumab in the Treatment of Familial Mediterranean Fever: A Systematic Review of the Literature

Mark Kacar,1 Sinisa Savic,1 Jeroen CH van der Hilst2,3 1Department of Clinical Immunology and Allergy, St James´s University Hospital, Leeds, UK; 2Department of Infectious Diseases and Immunity, Jessa Hospital, Hasselt, Belgium; 3BIOMED Research Institute, University of Hasselt, Hasselt, B...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Kacar M, Savic S, van der Hilst JCH
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2020
Materias:	familial mediterranean fever canakinumab anti-il1 therapy Pathology RB1-214 Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/668b92cb15a746a4b9d8c98d09e8d710
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:668b92cb15a746a4b9d8c98d09e8d710
record_format	dspace
spelling	oai:doaj.org-article:668b92cb15a746a4b9d8c98d09e8d7102021-12-02T10:59:48ZThe Efficacy, Safety and Tolerability of Canakinumab in the Treatment of Familial Mediterranean Fever: A Systematic Review of the Literature1178-7031https://doaj.org/article/668b92cb15a746a4b9d8c98d09e8d7102020-03-01T00:00:00Zhttps://www.dovepress.com/the-efficacy-safety-and-tolerability-of-canakinumab-in-the-treatment-o-peer-reviewed-article-JIRhttps://doaj.org/toc/1178-7031Mark Kacar,1 Sinisa Savic,1 Jeroen CH van der Hilst2,3 1Department of Clinical Immunology and Allergy, St James´s University Hospital, Leeds, UK; 2Department of Infectious Diseases and Immunity, Jessa Hospital, Hasselt, Belgium; 3BIOMED Research Institute, University of Hasselt, Hasselt, BelgiumCorrespondence: Jeroen CH van der HilstDepartment of Infectious Diseases and Immunity, Jessa Hospital, Stadsomvaart 11, Hasselt 3500, BelgiumTel +32 11309485Email jeroen.vanderhilst@jessazh.beAbstract: Familial Mediterranean Fever (FMF) is the most prevalent genetic autoinflammatory disorder. In most patients, treatment with colchicine can prevent attacks of fever and inflammation. However, 5%– 10% of patients are resistant to colchicine treatment, while a similar percentage cannot tolerate colchicine in doses needed to prevent attacks. For these patients, Canakinumab, a full human antibody against IL-1β, has been approved recently by the FDA and EMA. In this article, we present a systematic review of the long-term efficacy, safety, and tolerability of Canakinumab in FMF patients who cannot tolerate colchicine or who are resistant to colchicine treatment.Keywords: familial mediterranean fever, Canakinumab, anti-IL1 therapyKacar MSavic Svan der Hilst JCHDove Medical Pressarticlefamilial mediterranean fevercanakinumabanti-il1 therapyPathologyRB1-214Therapeutics. PharmacologyRM1-950ENJournal of Inflammation Research, Vol Volume 13, Pp 141-149 (2020)
institution	DOAJ
collection	DOAJ
language	EN
topic	familial mediterranean fever canakinumab anti-il1 therapy Pathology RB1-214 Therapeutics. Pharmacology RM1-950
spellingShingle	familial mediterranean fever canakinumab anti-il1 therapy Pathology RB1-214 Therapeutics. Pharmacology RM1-950 Kacar M Savic S van der Hilst JCH The Efficacy, Safety and Tolerability of Canakinumab in the Treatment of Familial Mediterranean Fever: A Systematic Review of the Literature
description	Mark Kacar,1 Sinisa Savic,1 Jeroen CH van der Hilst2,3 1Department of Clinical Immunology and Allergy, St James´s University Hospital, Leeds, UK; 2Department of Infectious Diseases and Immunity, Jessa Hospital, Hasselt, Belgium; 3BIOMED Research Institute, University of Hasselt, Hasselt, BelgiumCorrespondence: Jeroen CH van der HilstDepartment of Infectious Diseases and Immunity, Jessa Hospital, Stadsomvaart 11, Hasselt 3500, BelgiumTel +32 11309485Email jeroen.vanderhilst@jessazh.beAbstract: Familial Mediterranean Fever (FMF) is the most prevalent genetic autoinflammatory disorder. In most patients, treatment with colchicine can prevent attacks of fever and inflammation. However, 5%– 10% of patients are resistant to colchicine treatment, while a similar percentage cannot tolerate colchicine in doses needed to prevent attacks. For these patients, Canakinumab, a full human antibody against IL-1β, has been approved recently by the FDA and EMA. In this article, we present a systematic review of the long-term efficacy, safety, and tolerability of Canakinumab in FMF patients who cannot tolerate colchicine or who are resistant to colchicine treatment.Keywords: familial mediterranean fever, Canakinumab, anti-IL1 therapy
format	article
author	Kacar M Savic S van der Hilst JCH
author_facet	Kacar M Savic S van der Hilst JCH
author_sort	Kacar M
title	The Efficacy, Safety and Tolerability of Canakinumab in the Treatment of Familial Mediterranean Fever: A Systematic Review of the Literature
title_short	The Efficacy, Safety and Tolerability of Canakinumab in the Treatment of Familial Mediterranean Fever: A Systematic Review of the Literature
title_full	The Efficacy, Safety and Tolerability of Canakinumab in the Treatment of Familial Mediterranean Fever: A Systematic Review of the Literature
title_fullStr	The Efficacy, Safety and Tolerability of Canakinumab in the Treatment of Familial Mediterranean Fever: A Systematic Review of the Literature
title_full_unstemmed	The Efficacy, Safety and Tolerability of Canakinumab in the Treatment of Familial Mediterranean Fever: A Systematic Review of the Literature
title_sort	efficacy, safety and tolerability of canakinumab in the treatment of familial mediterranean fever: a systematic review of the literature
publisher	Dove Medical Press
publishDate	2020
url	https://doaj.org/article/668b92cb15a746a4b9d8c98d09e8d710
work_keys_str_mv	AT kacarm theefficacysafetyandtolerabilityofcanakinumabinthetreatmentoffamilialmediterraneanfeverasystematicreviewoftheliterature AT savics theefficacysafetyandtolerabilityofcanakinumabinthetreatmentoffamilialmediterraneanfeverasystematicreviewoftheliterature AT vanderhilstjch theefficacysafetyandtolerabilityofcanakinumabinthetreatmentoffamilialmediterraneanfeverasystematicreviewoftheliterature AT kacarm efficacysafetyandtolerabilityofcanakinumabinthetreatmentoffamilialmediterraneanfeverasystematicreviewoftheliterature AT savics efficacysafetyandtolerabilityofcanakinumabinthetreatmentoffamilialmediterraneanfeverasystematicreviewoftheliterature AT vanderhilstjch efficacysafetyandtolerabilityofcanakinumabinthetreatmentoffamilialmediterraneanfeverasystematicreviewoftheliterature
_version_	1718396357199265792

The Efficacy, Safety and Tolerability of Canakinumab in the Treatment of Familial Mediterranean Fever: A Systematic Review of the Literature

Ejemplares similares